Today's Research Reports on Stocks to Watch: Moleculin Biotech and Conatus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / June 27, 2017 / Moleculin Biotech and Conatus Pharmaceuticals were big winners on the NASDAQ yesterday. Moleculin in particular was a huge gainer scoring almost 40% in gains at the close. The company has entered into an agreement with a physician at the Mayo Clinic to do further research on its WP1066 molecule to treat DIPG, a rare pediatric brain tumor. Conatus also soared to gains of almost 10% at the close after receiving Orphan Drug Designation from the FDA for its IDN-7314 drug candidate.
RDI Initiates Coverage on:
Moleculin Biotech, Inc.
https://ub.rdinvesting.com/news/?ticker=MBRX
Conatus Pharmaceuticals Inc.
https://ub.rdinvesting.com/news/?ticker=CNAT
Moleculin Biotech, Inc. was one of the biggest gainers on the NASDAQ yesterday. Shares closed up 38.18% on very impressive volume after the preclinical pharma company announced that it has entered into an agreement with a Mayo Clinic physician. The agreement will enable additional research on the company's WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor called Diffuse Intrinsic Pontine Gliomas (DIPG). CEO Walter Klemp commented, "Independent research now suggests that WP1066 is capable of tumor suppression in xenografts of human brain tumors transplanted into mice. So, we are eager to move WP1066 into the clinic as quickly as possible." Studies at the Mayo Clinic have indicated that this rare form of pediatric brain tumor could be particularly sensitive to the inhibition of the activated form of a cell-signaling protein called STAT3, which is a primary target of WP1066. Preliminary studies have shown there has been significant anti-tumor activity of WP1066 in DIPG in both vitro and vivo tumor models.
Access RDI's Moleculin Biotech Research Report at:
https://ub.rdinvesting.com/news/?ticker=MBRX
Conatus Pharmaceuticals Inc.'s shares closed up 9.61% on Monday. The company had exciting FDA news that had traders pretty pumped. The FDA has granted Orphan Drug Designation to the company's IDN-7314 drug candidate for the treatment of primary sclerosing cholangitis (PSC). The company's IDN-7314 candidate is an orally active-pan-caspase protease inhibitor that has demonstrated reduction of relevant biomarkers in two preclinical models of the disease PSC, which affects a person's bile ducts in the liver and can cause cirrhosis and liver failure. CEO Steven J. Mento Ph.D. commented, "The FDA's Orphan Drug Designation of IDN-7314 for the treatment of PSC highlights the need for novel therapies for this patient population." He further said, "There are no curative or disease-modifying treatments for PSC itself. Continued progression over time ultimately leads to liver transplant or liver failure. For Conatus, the Orphan Drug Designation provides a potential opportunity to address an important unmet medical need and expand the company's drug development pipeline beyond emricasan. We will continue to evaluate this opportunity along with others as we advance toward the announcement of our initial pipeline plans later in 2017.”
Access RDI's Conatus Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=CNAT
Our Actionable Research on Moleculin Biotech, Inc. (NASDAQ: MBRX) and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
